Open for Enrollment Soon

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Phase I Rux+Fosta for Steroid Refractory cGvHD (Graft versus Host Disease) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug called fostamatinib (the study drug) is beneficial for cGvHD when it is used in combination with a standard of care drug, ruxolitinib. We want to know if the study drug can improve relief from cGvHD symptoms.

What is the Condition Being Studied?

Chronic Graft Versus Host Disease (cGvHD)

Who Can Participate in the Study?

Adults ages 18-80 who:

Are diagnosed with cGvHD
Are either dependent on steroids or non-responsive to steroids
Have received an allogeneic hematopoietic cell transplant (HCT)

For more information about who can join this study, please contact one of the study team members below:

Chenyu Lin: chenyu.lin@duke.edu or 919-684-8964

Michelle Araque: michelle.araque@duke.edu or 919-660-0982

Age Group

Adults

What is Involved?

If you choose to join the study, you will:

Have a physical exam done and medical history taken
Have vital signs taken
Have blood draws
Have a pulmonary function (breathing) test
Fill out questionnaires
Take a combination of the study drug and ruxolitinib (pills that you take by mouth)